- Trials with a EudraCT protocol (1,410)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,410 result(s) found for: S 100 Protein.
Displaying page 1 of 71.
EudraCT Number: 2017-000108-42 | Sponsor Protocol Number: V505-001 | Start Date*: 2017-01-27 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Phase IIa Randomized, Double-Blinded, Controlled With GARDASIL™ Clinical Trial to Study the Tolerability and Immunogenicity of V505 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like-Particl... | |||||||||||||
Medical condition: vaccination against HPV infection/related disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000109-19 | Sponsor Protocol Number: V502-001 | Start Date*: 2017-01-27 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging Study of Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58... | |||||||||||||
Medical condition: vaccination against HPV infection/related disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001367-24 | Sponsor Protocol Number: 217043 | Start Date*: 2021-11-16 | |||||||||||
Sponsor Name:GlaxoSmithKline SA | |||||||||||||
Full Title: A Phase II, randomized, partially blinded study to assess the safety, tolerability and immunogenicity of meningococcal combined ABCWY vaccine when administered to healthy infants. | |||||||||||||
Medical condition: Healthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Temporarily Halted) DE (Trial now transitioned) PL (Trial now transitioned) IT (Temporarily Halted) FI (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004741-37 | Sponsor Protocol Number: 212458 | Start Date*: 2021-06-21 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase I/II, randomised, controlled study to assess the safety, effectiveness and immune response of meningococcal combined ABCWY vaccine when administered to healthy adults (Phase I) and to healt... | ||
Medical condition: Healthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) FI (Completed) Outside EU/EEA PL (Ongoing) SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003268-37 | Sponsor Protocol Number: 205239 | Start Date*: 2018-09-26 |
Sponsor Name:GlaxoSmithKline Biologicals SA | ||
Full Title: A Phase IIIB, Observer-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine when... | ||
Medical condition: Healthy subjects (to assess the safety and immunogenicity of Bexsero and Prevnar13 when administered concomitantly with RIV to healthy infants). | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2017-000111-16 | Sponsor Protocol Number: V501-029 | Start Date*: 2017-01-11 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in healthy females 9 to 15 years of age in India. | |||||||||||||
Medical condition: vaccination against HPV infection/related disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006579-41 | Sponsor Protocol Number: ANG3070-CKD-201 | Start Date*: 2022-03-07 | |||||||||||
Sponsor Name:Angion Biomedica Corp. | |||||||||||||
Full Title: A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of Safety and Efficacy Of ANG-3070 in Patients with Primary Glomerular Disease and Persistent Proteinuria | |||||||||||||
Medical condition: Primary glomerular disease and persistent proteinuria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005093-38 | Sponsor Protocol Number: V503-004 | Start Date*: 2016-07-05 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck Co., Inc | |||||||||||||
Full Title: An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27-... | |||||||||||||
Medical condition: Prevention of cervical,vulvar,vaginal, and anal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by HPV Types 6,11,16,18,31,33,45,52,58 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) FI (Completed) AT (Completed) ES (Completed) IT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006686-32 | Sponsor Protocol Number: EC07/90573 | Start Date*: 2008-05-22 |
Sponsor Name:FUNDACIÓN INVESTIGACIÓN BIOMEDICA DEL HOSPITAL CLINICO SAN CARLOS | ||
Full Title: Identificación de biomarcadores proteicos asociados a resistencia a la aspirina y a tienopiridinas en pacientes con cardiopatía isquémica establecida. (ESTUDIO BIRAT). Identification of new protei... | ||
Medical condition: To determine proteins in plasma, leukocytes and platelets associated with aspirin resistance syndrome in stable coronary artery disease patients that may allow us to identify them.It is probably th... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023393-39 | Sponsor Protocol Number: GDS01C | Start Date*: 2011-01-13 | |||||||||||
Sponsor Name:Sanofi Pasteur MSD S.N.C | |||||||||||||
Full Title: A Randomized, Double-Blinded, Controlled with GARDASIL® (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)), Phase III Clinical Trial to Study the Immunogenicity and Toler... | |||||||||||||
Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) Types 6, ... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Female | ||||||||||||
Trial protocol: FI (Completed) BE (Completed) SE (Completed) ES (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001972-46 | Sponsor Protocol Number: SKNt-001-CP4 | Start Date*: 2019-05-14 | |||||||||||
Sponsor Name:Fresenius Kabi Deutschland GmbH | |||||||||||||
Full Title: Reaching Protein Target with SmofKabiven® extra Nitrogen Versus Olimel N9E: A Prospective, Randomised, Active-controlled, Patient-blinded, Multicentre Clinical Trial During the Early Phase of Acute... | |||||||||||||
Medical condition: Parenteral nutrition (PN) when oral or enteral nutrition (ON or EN) is impossible, insufficient, or contraindicated in the early phase of critical illness | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002215-22 | Sponsor Protocol Number: LTS16294 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Bioverativ Therapeutics Inc. | |||||||||||||
Full Title: A Phase 3 open-label, multicenter study of the long-term safety and efficacy of intravenous recombinant coagulation factor VIII Fc-von willebrand factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN; BIVV... | |||||||||||||
Medical condition: Hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) FR (Ongoing) GR (Ongoing) IE (Trial now transitioned) SE (Trial now transitioned) HU (Ongoing) DE (Trial now transitioned) BG (Trial now transitioned) IT (Ongoing) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000948-60 | Sponsor Protocol Number: C3511002 | Start Date*: 2021-01-19 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 2b TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY INFANTS 2 AND 6 MONTHS OF AGE | |||||||||||||
Medical condition: Invasive Meningococcal Disease (IMD) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004823-39 | Sponsor Protocol Number: CC-5013-MM-020/IFM 07-01 | Start Date*: 2008-04-03 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, 3-ARM STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) PLUS LOW-DOSE DEXAMETHASONE WHEN GIVEN UNTIL PROGRESSIVE DISEASE OR FOR 18 FOUR-WEEK... | |||||||||||||
Medical condition: Previously untreated multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) IE (Prematurely Ended) IT (Completed) AT (Completed) ES (Completed) SE (Completed) BE (Completed) PT (Completed) DE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006950-30 | Sponsor Protocol Number: CLOU064I12201 | Start Date*: 2022-08-02 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
Full Title: A one month, investigator and participant blinded study to investigate the efficacy and safety of remibrutinib (LOU064) at multiple dose levels in adult participants with peanut allergy | |||||||||||||
Medical condition: Allergy, Peanut | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000924-13 | Sponsor Protocol Number: VAN00010 | Start Date*: 2023-12-21 | |||||||||||
Sponsor Name:Sanofi Pasteur Inc. | |||||||||||||
Full Title: A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity study to assess Pentavalent Meningococcal ABCYW Vaccine formulations in Adults (18 to 25 years of age) and Adolescents (10 to 17 yea... | |||||||||||||
Medical condition: Bacterial infections and mycoses | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004461-41 | Sponsor Protocol Number: MET59 | Start Date*: 2020-02-14 | |||||||||||
Sponsor Name:Sanofi Pasteur Inc | |||||||||||||
Full Title: Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults | |||||||||||||
Medical condition: Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y and W) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012136-33 | Sponsor Protocol Number: IPH2101-201 | Start Date*: 2009-07-08 | |||||||||||
Sponsor Name:Innate Pharma | |||||||||||||
Full Title: Open randomised phase II study evaluating the anti-tumour activity, safety and pharmacology of two different dose regimens of IPH 2101, a human monoclonal anti-KIR antibody, in patients with multip... | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000110-35 | Sponsor Protocol Number: V501-046 | Start Date*: 2017-01-11 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: Evaluation of Safety and Immunogenicity of GARDASIL™ in Healthy Females Between 9 and 26 Years of Age in SubSaharan Africa. | |||||||||||||
Medical condition: Vaccination against HPV infection/related disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001665-37 | Sponsor Protocol Number: MEQ00071 | Start Date*: 2021-03-22 | |||||||||||
Sponsor Name:Sanofi Pasteur | |||||||||||||
Full Title: Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix®, and When Administered Alone or Concomitantly with 9vHPV and Tdap-IPV Vaccines in Healthy Adolescents | |||||||||||||
Medical condition: Meningococcal infection | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) IT (Ongoing) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.